A/Prof Amit Khot
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
110 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.
DOI: 10.1182/blood.20260347042026
Journal article
MM-1092: Trial in Progress: QUINTESSENTIAL-2, a Phase 3 Study of Arlocabtagene Autoleucel vs Standard of Care in Adult Patients With Relapsed/Refractory Multiple Myeloma Exposed to Lenalidomide
DOI: 10.1016/s2152-2650(26)02983-62026
Journal article
POSTER: MM-1092: Trial in Progress: QUINTESSENTIAL-2, a Phase 3 Study of Arlocabtagene Autoleucel vs Standard of Care in Adult Patients With Relapsed/Refractory Multiple Myeloma Exposed to Lenalidomide
DOI: 10.1016/s2152-2650(26)01409-62026
Journal article
Cytomegalovirus reactivation in patients with multiple myeloma receiving bispecific antibodies
DOI: 10.1182/bloodadvances.20250195632026
Research grants (other domestic)
Scaling the Living Better With Myeloma Survivorship Model to Regional Victoria: A Pilot Feasibility Implementation Study at Bendigo Health Regional Cancer Centre
2026
Journal article
QUINTESSENTIAL-2: A phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide.
DOI: 10.1200/jco.2026.44.16_suppl.tps75772026
Journal article
Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial
DOI: 10.1158/1078-0432.CCR-25-3216
RECENT SCHOLARLY WORKS
2026
Journal article
Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies
DOI: 10.1016/S2352-3026(26)00005-02026
Journal article
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
DOI: 10.1182/bloodadvances.20250166462026
Journal article
Trial in Progress: QUINTESSENTIAL-2—a phase 3 Study of Arlocabtagene Autoleucel Versus Standard of Care in Adult Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Exposed to Lenalidomide
DOI: 10.1016/j.jtct.2025.12.2792026
Journal article
TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE
DOI: 10.3324/haematol.2026.s2.14111